Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge.
Antisense oligonucleotide (AO)-mediated exon skipping is a promising new therapy for Duchenne muscular dystrophy (DMD), recently demonstrating proof of principle for restoring the absent dystrophin protein in DMD patients. However, the range of AO chemistries available for exon skipping is limited;...
主要作者: | Wood, M |
---|---|
格式: | Journal article |
语言: | English |
出版: |
2010
|
相似书籍
-
Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy.
由: Goyenvalle, A, et al.
出版: (2011) -
Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy.
由: Koo, T, et al.
出版: (2013) -
PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.
由: Hammond, S, et al.
出版: (2010) -
Progress in the Treatment of Antisense Oligonucleotides in Duchenne Muscular Dystrophy
由: XU Tingting, et al.
出版: (2022-04-01) -
Casimersen (AMONDYS 45™): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy
由: Milyard Assefa, et al.
出版: (2024-04-01)